Stock Price & Analysis

Based on the provided data and recent developments, here's a concise analysis of PYXS stock:

Technical Analysis

The stock is currently trading at $1.50, showing weak technical indicators with RSI at 36.15, suggesting oversold conditions. The stock is trading below its 20-day moving average of $1.59, indicating bearish short-term momentum.

Recent Developments According to recent news, Pyxis Oncology announced a strategic portfolio prioritization focusing on PYX-201 while deprioritizing PYX-106. This decision aims to allocate resources more efficiently toward advancing their lead asset. The company expects preliminary data from various trials in 2H2025 and 1H2026.

Financial Position According to, PYXS has:

• Cash and equivalents: $12.1 million
• Marketable securities: $132.8 million
• Total liquidity: $144.9 million
• Quarterly cash burn: ~$14.7 million
• Estimated cash runway: 2.5 years

Analyst Ratings

Recent analyst actions show mixed sentiment:

• RBC Capital: Price target lowered to $8 from $10, maintains Buy rating
• HC Wainwright: Price target reduced to $5 from $7, maintains Strong Buy
• William Blair: Downgraded to Hold from Buy

Conclusion Selling PYXS stock appears to be the prudent choice at current levels due to weak technical indicators and recent strategic shifts creating uncertainty around near-term execution.

Based on the available data and technical analysis, here is the price prediction for PYXS stock in 2025:

PYXS is expected to trade between $1.83-2.03 by mid-2025, driven by positive preliminary data expected from PYX-201's dose expansion studies in H2 2025. The company's focus on advancing PYX-201 after deprioritizing PYX-106 and sufficient cash runway into H2 2026 provides stability for near-term operations. Technical indicators show the stock is currently oversold with RSI at 36.15 and trading near key Fibonacci support levels of $1.43.

The S1 support level for PYXS Stock is $1.42 ,The R1 resistant level for PYXS Stock is $1.68.

As of the end of day on 2025-01-23, the price of PYXS Stock was $1.658.

The target price for PYXS Stock according to analyst rating is 9.60, with the highest price target at 13.00 and the lowest at 5.00. Analysts have a Strong Buy rating on PYXS Stock overall.

The market cap of PYXS is $97.5M.

Based on the provided data, I'll analyze if PYXS is overvalued.

PYXS is currently undervalued considering its pipeline potential and analyst targets. The stock trades at $1.50, significantly below the consensus price target of $8.00 from multiple analysts. Recent portfolio prioritization focusing on PYX-201 shows promising preliminary data with 50% objective response rate in head and neck cancer patients.

The company's decision to deprioritize PYX-106 to allocate resources toward advancing PYX-201 is strategically sound, with cash runway extending into second half of 2026. The current price represents a substantial discount to the company's book value and development stage assets.

Recent analyst ratings remain predominantly bullish despite some mixed trial results, with price targets ranging from $5-13, suggesting significant upside potential from current levels. The stock's sharp decline in November 2024 appears overdone given the overall positive trial data and strong balance sheet.

The market's negative reaction to safety concerns appears excessive given PYX-201's demonstrated efficacy across multiple tumor types. With $144.9 million in liquidity and no debt, the current market cap of $107 million significantly undervalues the company's assets and pipeline potential.

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Based on the available data and recent developments, here's the price prediction for PYXS stock by 2030:

PYXS stock is projected to reach $4.50-5.00 by 2030, driven by the company's strategic focus on its lead program PYX-201 which has shown promising preliminary results in treating various solid tumors. The company's current cash position is expected to fund trials into 2026, with multiple catalysts including preliminary data expected in 2H2025 and 1H2026. However, recent safety concerns and portfolio prioritization decisions create significant uncertainty in this projection.

Note: This projection assumes successful clinical trials and regulatory approvals. The biotech sector is highly volatile and speculative, especially for clinical-stage companies like Pyxis Oncology.

PYXS has a total of 50 employees.